ClC-2 chloride channel activator
This page covers all ClC-2 chloride channel activator drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting ClC-2 chloride channel.
Targets
Marketed (1)
- lubiprostone (Amitiza) · Henry Ford Health System · Gastroenterology
Lubiprostone activates ClC-2 chloride channels in the intestinal epithelium to increase intestinal fluid secretion and promote bowel movements.
Phase 3 pipeline (1)
- Lubiprostone 24 · Sucampo Pharma Americas, LLC · Gastroenterology
Lubiprostone is a ClC-2 chloride channel activator that increases intestinal fluid secretion and promotes bowel motility to relieve constipation.
Patent intelligence
- clc 2 chloride channel activator patent landscape — aggregated cliff calendar, attackable patents, originator estates